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ABSTRACT 
Objective: The main objective of the research work is to develop a single unit non-effervescent drug delivery system of Loratadine (LTD) by direct 
compression process to prolong the gastric residence time (GRT). 
Methods: LTD non-effervescent floating tablets were prepared with different polymers like hydroxypropyl methylcellulose (HPMC) K15M, HPMC 
K100M (i.e.: 1:1, 1:2, 1:3) as release retardants. Glyceryl behenate (Compritol 888 ATO) and Glyceryl palmitostearate (Precirol ATO 5) were used 
(1:1, 1:2, 1:3) as low-density lipids to impart buoyancy for longer period. 
Results: The drug (LTD) and excipient (i.e. HPMC, low-density lipid aids, etc.,) interaction studies were carried out by Fourier Transform Infrared 
Spectroscopy (FTIR) and there was no likely interaction involving them. The developed LTD floating matrix tablets were characterized by pre and 
post-compression parameters and all results were found within the pharmacopoeial limits. The cumulative percentage of drug release ranges from 
56.87±0.25 % (F12) to 99.87±0.09 % (F2). The drug release profiles of the all formulations (F1 to F12) were subjected to various pharmacokinetic 
parameters and the optimized formulation (F3) followed the Korsmeyer Peppas (R2=0.996) model with non-Fickian diffusion (n>0.5). The obtained 
data by radiographic images of F3 formulation showed the GRT of 6±0.5 h (n=3). 
Conclusion: Hence, from all evaluation studies, it was evident that F3 formulation was optimized (99.82±1.63 % drug release in 12 h).  
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Oral directions of drug administration have broad recognition of up 
to 50-60% of whole dosage forms [1]. Oral drug delivery (i.e.: 
tablets, capsule, powders, emulsions, suspensions, etc.,) is 
considered as the most common, most popular, convenient and safe 
(when compared to parental route) [2]. Solid dosage forms are more 
popular because of ease of administration, accurate dosage, self-
medication, pain avoidance and most importantly the patient 
compliance [3-5]. The majority accepted solid dosage forms are 
tablets and capsules; one of the important drawbacks of solid dosage 
forms; especially solids are not recommended to pediatrics, 
geriatrics and unconscious patients [6-8]. Gastrointestinal 
physiology offers additional flexibility in dosage form design than 
the popularity of other routes [9, 10]. 
The term extended-release (i.e. controlled release, sustained release, 
etc,) formulations are used to categorize drug delivery systems 
(DDS) that are considered to accomplish or extend phase of time 
subsequent for administration of a single dose and as an alternative 
to multiple dosage, having a benefit that the drug release was long-
standing and it has been noticeable to pharmaceutical 
manufacturing [11-15]. LTD is a lipophilic, non-sedating H1 blocker 
and used to treat seasonal allergic rhinitis having low bioavailability 
(40%), and biological half-life (8 h). So, patients can avoid frequent 
administrations in a day [16-20]. Such frequent drug administration 
may reduce patient obedience and therapeutic effectiveness [21-25]. 
To overcome the above-mentioned problems it is required to convey 
the single dose for an extended period. Besides, LTD shows the 
greatest solubility at acidic pH and it is an appropriate candidate for 
the expansion of gastroretentive drug delivery systems (GRDDS). 
The aim of extended release (ER) DDS is to be customized in such a 
method with the intention; extra residence time in the stomach to 
release the drug before the absorption window. The goal of GRDDS 
is to provide a beneficial quantity of the drug to the appropriate 
location in the body and sustain the required drug concentration. To 
avoid the problems associated with the delivery of LTD, we planned 
to formulate LTD in an extended-release floating matrix formulation. 
This will allow us to reduce the frequency of administration and 
enhances patient compliance. To achieve the goal we have used low-
density lipids or floating aids like compritol and precirol that can 
allow the formulation to stay on top of the gastric contents. It will 
avoid the first-pass metabolism and will improve the bio-availability 
of the formulation. 
MATERIALS AND METHODS 
Materials 
Loratadine received as a gift sample from Hetero Labs Ltd, 
Hyderabad, India. HPMC K15 M and HPMC K100 M procured from B 
and K Technologies, China. Compritol and precirol were purchased 
from Gattefosse, Germany. MCC–(Avicel PH 200), Aerosil and 
Magnesium stearate from SD Fine Chemicals Ltd., Mumbai. 
Hydrochloric acid from Merck specialities Pvt. Ltd. Mumbai, India 
Methods 
Pre-compression characterization 
Drug excipient compatibility studies 
Fourier transform infrared spectroscopy (FTIR) 
The drug excipient compatibility study was carried out by FTIR with 
in the frequency range of 4000–400 cm-1 and 4 cm-1 resolution. The 
IR spectra for the test samples were obtained using the KBr disk 
method using an FTIR (Star Tech Labs Pvt. Ltd., Hyderabad) [26]. 
Differential scanning calorimetry (DSC) 
The differential thermal analyzer was used to find out the presence 
of any interaction among drug and excipients. About 5-15 mg of the 
sample was taken in pierced DSC aluminium pan and scanned in the 
temperature range of 50-300 °C and the heating rate was 10 
°C/min.; nitrogen served as purged gas and the system was cooled 
down by liquid nitrogen [27]. 
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Flow properties of the powder blend 
The powder mixtures of different formulations were evaluated for 
angle of repose (ɵ), bulk density (gm/cm3), tapped density 
(gm/cm3), Carr’s index or compressibility index (%) and Hausner’s 
ratio. [28] And the evaluation test results are shown in table 2. 
Angle of repose (ɵ) 
The fixed funnel method was employed to measure the ‘ɵ’ and it was 
determined by below formula  
 
Here ‘ɵ’ is the angle of repose, ‘h’ is the height of the pile and ‘r’ is the 
radius of the base. 
Carr’s index or compressibility index (%) 
Bulk density (BD) and tapped densities (TD) were determined by 
the following formulas. 
 
The carr’s index was calculated by the following formula 
 
Hausner’s ratio 
Hausner’s ratio was calculated by the following formula 
 
Construction of loratadine calibration curve 
The study started with the construction of a standard calibration curve 
of Loratadine. The standard graph of LTD with 0.1N hydrochloric acid 
(HCl) was plotted by taking concentration ranging from 5µg/ml to 
45µg/ml on X-axis and absorbance values on Y-axis [29-30].  
Preparation of LTD non-effervescent floating matrix tablets 
Floating tablets containing LTD were prepared by a direct 
compression technique [31]. Polymers and floating aids ratios 
were taken as 1:1, 1:2, and 1:3 (table 1). LTD and all other 
additives are precisely weighed and sieved through 44 mesh.  
The LTD was well mixed with a magnitude of necessary polymers 
(HPMC K15M, HPMC K100M), floating aids (Compritol 888 ATO and 
Precirol ATO 5), MCC (Avicel PH 200) in geometric proportions. 
After that the blend was lubricated with previously weighed, sieved 
magnesium stearate and aerosil. Finally, about 100 mg of the 
lubricated blend was subjected to compression by using a 6 mm 
circular standard flat-faced punch on 10 stations rotary tablet 
punching machine (i.e. Karnavathi, Gujarat, India) [32]. 
 
Table 1: Composition of LTD floating matrix tablets 
*Formulation (mg/tablet) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Drug (LTD) 10 10 10 10 10 10 10 10 10 10 10 10 
HPMC K15M 10 20 30 - - - 10 20 30 - - - 
HPMC K100M - - - 10 20 30 - - - 10 20 30 
Compritol 888 ATO 10 20 30 - - - 5 10 15 5 10 15 
Precirol ATO 5 - - - 10 20 30 5 10 15 5 10 15 
Avicel PH 200 65 45 25 65 45 25 65 45 25 65 45 25 
Talc 2 2 2 2 2 2 2 2 2 2 2 2 
Aerosil 2 2 2 2 2 2 2 2 2 2 2 2 
Magnesium stearate 1 1 1 1 1 1 1 1 1 1 1 1 
Total weight 100 100 100 100 100 100 100 100 100 100 100 100 
*Each value represents mean±SD (n=30) 
 
Post-compression characterization 
The above-compressed LTD floating tablets should be characterized 
by several specifications, which include weight variation, thickness, 
friability; hardness and drug content uniformity, etc., were shown in 
table 3.  
Weight variation (mg) 
The weight of the prepared LTD floating tablets (i.e. n=20; randomly 
from every batch, then average weight should be well-thought-out) 
determined by using an electronic balance (Shimadzu, AUX220, 
Japan) [33]. 
Thickness (mm) 
The thickness of the prepared LTD floating tablets (i.e. n=20) 
measured by, vernier calipers, tablet thickness is reliable from batch 
to batch or within a batch only if the tablet granulation or dust mix is 
satisfactorily dependable on particle size and size distribution, if the 
punch tooling is of regular length, and the tablet press is clean and in 
good working order. Thickness must be controlled for consumer 
acceptance of the product, and to facilitate packaging [34].  
Friability (%) 
The friability test was performed with prepared LTD floating tablets 
(i.e. n=20; unintentionally from the entire batches) by placing in 
Roche friabilator and allowed to make 100 revolutions (i.e. 25 rpm 
for 4 min).  
 
Where W1 is the initial weight of tablets; W2 is the final weight of de-
dusted tablets; and the values<1% is usually good [35]. 
Hardness (Kg/cm2) 
The hardness (i.e. n=6; erratically from every grouping after that 
middling should be deliberate) of the prepared LTD floating tablets 
were measured by using Pfizer type hardness tester (Dolphin 
Pharmacy Instruments, Pvt. Ltd., Mumbai). By this test, the tablet 
mechanical potency or crushing strength will be determined and the 
average hardness with standard deviation was reported [36]. 
Content uniformity (%) 
The prepared LTD floating tablets (n=6) were collected at random 
and pulverized. Several fine particles corresponding to the weight of 
1 tablet was transferred into 100 ml volumetric flask (VF), to this 
100 ml of methanol was added, then the solution was subjected to 
sonication for about 2 h. The solution was up to the mark with an 
equivalent concentration of the standard solution (i.e. 0.1N HCl) 
[37]. 
In vitro buoyancy studies (h) 
The in vitro floating (n=3) was determined by the reported method. 
Here, the prepared LTD was placed in a 100 ml beaker containing 
0.1N HCl. The time required to float the tablet or rise from the 
bottom of the beaker to the surface of the liqid called floating lag 
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time (FLT) and the total duration of tablet float on the surface is 
called as total floating time (TFT) [38]. 
In vitro dissolution (%) 
The drug release or in vitro dissolution studies (i.e. n=6) of LTD non-
effervescent floating tablets were carried out with USP dissolution 
type–II (i.e. paddle) method at 50 rpm in 900 ml of 0.1N HCl as 
dissolution medium, maintained at 37 °C±0.5 °C. About to 5 ml of 
aliquot (i.e. sample) was withdrawn at predetermined time intervals 
for every 1 hour up to 12 h and replaced with 5 ml of fresh medium 
(i.e. 0.1N HCl) each time. The samples were analyzed by using a 
double beam UV visible spectrophotometer (Elico, SL210, 
Hyderabad) at 280 nm. By using a standard calibration curve, 
calculate the cumulative percentage of drug release [39-40]. 
In vivo buoyancy studies (h) 
In vivo gastric retention time (GRT) was determined by X-ray 
procedure in healthy human volunteers (n=3). The procedure of the 
radiographic studies was approved by the institutional human 
ethical committee (IHEC). For in vivo study (i.e.: Proposal no. IRB-
AGI/2018-19/11), Barium sulphate (BaSO4) containing LTD floating 
tablets were prepared by a similar method as described in the 
formulation. In this revision, part of the LTD was replaced using 
BaSO4 each one of the ingredients remained equivalent [41]. 
Mechanism of drug release kinetics 
The drug release data of LTD prepared floating matrix tablets were 
fitted into different kinetic models representing Zero order, First 
order, Higuchi and Peppas model to know the release mechanism 
[42-45]. 
RESULTS AND DISCUSSION 
Construction of loratadine calibration curve 
The maximum concentration (λmax) of LTD in 0.1N HCl was scanned 
and found to have the maximum absorbance at 280 nm. The standard 
graph of LTD in 0.1 N HCl was shown in fig. 1 by taking concentration 
ranging from 5µg/ml to 45µg/ml and a good correlation was obtained 
with a regression coefficient (R2) value of 0.998. 
 
 
Fig. 1: Standard graph of LTD; (n=1) 
 
 
Fig. 2: FTIR spectrum of the pure drug; (n=1) 
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Fig. 3: FTIR spectrum of optimized formulation (F3); (n=1) 
 
Pre-compression characterization 
Drug excipient compatibility studies 
The drug excipient compatibility study was carried out by using DSC 
and FTIR. FTIR is one of the most powerful analytical techniques 
when it comes to the determination of the presence of various 
functional groups and DSC is a thermo analytical method in which 
the differentiation in the sum of heat required to raise the 
temperature of the sample and reference is precisely the same. 
Fourier transform infrared spectroscopy (FTIR) 
The spectral laboratory analysis of pure drug (LTD) and optimized 
formulation (F3) as shown in fig. 2 and fig. 3 correspondingly; 
principle peaks at similar wave-numbers and in an optimized 
formulation (F3) some different wave numbers observed. 
However, these additional peaks were observed with physical 
mixtures, which could be due to the occurrence of polymers. The 
results advise that there is no reaction connecting the drug and 
polymers used in the current study.  
Differential scanning calorimetry (DSC) 
The thermal properties of the drug and the mixture of drugs and 
excipients are of important interest since this can help to assess the 
interaction among different components of the formulations (i.e., 
drug and other additives). Pure drug (LTD) and optimized 
formulation (F3) were subjected to DSC analysis. 
The DSC curve of a pure drug (i.e. fig. 4) showed a sharp endothermic 
peak at 136.11 °C. The optimized formulation (F3) drug and Compritol 
888 ATO showed a sharp endothermic peak at 135.10 °C (i.e. fig. 5). 
From the results, it was concluded that the drug was compatible 
with excipients used in formulations. 
Flow properties of the powder blend 
All prepared LTD powder blends are subjected to various 
parameters. The angle of repose ranges from 21.23±1.08 (F2) to 
31.40±1.05 (F8); Carr’s index ranges from 10.12±0.36 (F11) 
to15.36±0.47 (F4); Hausner’s ratio values ranges from 1.06±1.01 
(F9) to 1.26±0.55 (F7). From the above results, the powder blends 
(i.e. F1 to F12) showed well to excellent flow properties [46]. 
 
 
Fig. 4: DSC thermogram of pure drug (LTD); (n=1) 
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Fig. 5: DSC thermogram of optimized formulation (F3); (n=1) 
 
Table 2: Pre-compression characterization of LTD floating matrix tablets 
Formulation code Angle of reposea (Ɵ) Carr’s indexa (%) Hausner’s ratioa Flowability 
F1 26.51±1.26 12.38±1.04 1.12±0.44 Very good 
F2 21.23±1.08 10.54±0.89 1.10±0.38 Excellent 
F3 25.34±0.54 14.79±0.63 1.12±1.06 Very good 
F4 23.71±0.82 15.36±0.47 1.14±0.89 Very good 
F5 27.34±0.09 13.79±1.02 1.08±0.61 Good 
F6 23.23±0.06 14.54±0.68 1.17±0.74 Very good 
F7 21.34±0.84 12.79±1.09 1.26±0.55 Good 
F8 31.40±1.05 12.08±0.53 1.23±1.08 Good 
F9 28.52±1.02 15.32±1.27 1.06±1.01 Excellent 
F10 25.26±0.93 14.36±0.84 1.17±0.82 Very good 
F11 25.78±0.64 10.12±0.36 1.14±0.64 Very good 
F12 24.61±0.14 12.09±0.52 1.19±0.76 Very good 
aEach value represents mean±SD (n=3) 
 
Post-compression characterization 
Weight variation (n=20) 
The above-prepared formulations, 20 tablets from each batch (i.e. F1 
to F12) were individually weighed in milligrams (mg) on electronic 
balance (Shimadzu, AUX 220, Japan) and results in ranges from 
96.86±1.61 mg (F10) to 100.08±0.01 mg (F4). 
Thickness (n=20) 
Thickness is the only dimensional variable related to the 
compression process and is measured for all formulations (i.e. F1 to 
F12) by Vernier calipers and results range from 2.75±0.76 mm (F11) 
to 3.05±0.48 mm (F4).  
Friability (n=20) 
Initially, weigh the tablets (i.e. total weight of the tablets is W1) and after 
100 revolutions, de-dusted and reweighed (i.e. total weight of the tablets 
is W2) then worked at percentage weight loss and found the range from 
0.12±0.65 % (F10) to 0.49±0.07 % (F4). Friability test of each one 
formulation (F1 to F12) was found satisfactory (i.e.<1%) and viewing 
sufficient struggle to the mechanical shock and abrasion. 
Hardness (n=6) 
The hardness of the tablet was maintained for every batch, was 
instructed to play downwards on drug release because the effect of 
polymer concentration is the only area of interest and it was found 
between 4.27±1.08 kg/cm2 (F5) to 6.09±1.10 kg/cm2 
Drug content uniformity (n=6) 
The drug content was estimated by using UV visible 
spectrophotometer and the drug released from the entire prepared 
non-effervescent floating matrix tablets ranges from 96.16±1.15 % 
(F8) to 99.81±1.54 % (F7). 
In vitro buoyancy studies (n=3) 
All prepared LTD floating matrix tablet formulations (F1 to F12) 
were evaluated for buoyancy; 0.1N HCl used as medium and lipid 
aids used to float the tablet without using any gas generating 
agents such as sodium bicarbonate, citric acid, and tartaric acid 
etc,. To develop the desired non-effervescent floating matrix 
tablets of LTD, it was needed to optimize the buoyant properties 
and release rates. The floating aids (Compritol 888 ATO and 
Precirol ATO 5), slow down the water diffusion and results in the 
buoyancy of dosage form over an encoded time. There was no FLT, 
(i.e. all prepared LTD non-effervescent floating matrix tablets 
buoyant was zero seconds) which means by floating aids the 
prepared tablets directly float on the surface of the medium (i.e. 
0.1N HCl) and the TFT of all prepared LTD formulations (i.e. F1 to 
F12) showed ≥12 h [47, 48]. The in vitro buoyancy was shown in 
fig. 6 and fig. 7. 
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F1 98.88±1.01 2.97±0.61 0.22±1.25 4.95±0.71 97.25±0.87 Good 
F2 98.55±1.09 2.95±0.52 0.29±0.87 5.07±0.85 96.93±1.07 Very Good 
F3 99.06±1.03 2.85±0.63 0.41±0.35 5.12±0.59 99.86±1.54 Very Good 
F4 100.08±0.01 3.05±0.48 0.49±0.07 6.01±1.63 98.33±0.15 Excellent  
F5 99.55±1.25 2.89±0.31 0.21±1.15 4.27±1.08 97.90±1.09 Very Good 
F6 98.75±1.91 2.95±0.74 0.14±0.98 5.37±0.58 97.40±0.54 Excellent  
F7 98.88±1.02 3.04±0.79 0.21±0.56 5.32±1.53 99.81±1.54 Good 
F8 99.88±0.95 2.85±0.93 0.23±1.05 4.96±1.43 96.16±1.15 Very Good 
F9 98.01±1.06 3.01±0.67 015±1.54 5.61±1.12 98.31±0.76 Excellent  
F10 96.86±1.61 2.79±0.31 0.12±0.65 4.35±1.56 98.16±0.65 Good 
F11 98.98±0.75 2.75±0.76 0.24±1.34 6.09±1.10 98.83±0.20 Excellent  
F12 98.99±1.36 2.96±0.27 0.20±1.14 4.38±1.12 96.31±1.85 Excellent  
aEach value represents mean±SD (n=20); bEach value represents mean±SD (n=6) 
 
 
Fig. 6: Top views of in vitro buoyancy studies of optimized formulation (F3), a) at zero time b) at 3 h c) at 6 h d) at 12 h; (n=3, mean±SD) 
 
 
Fig. 7: Front view of in vitro buoyancy studies of optimized formulation (F3), a) at zero time b) at 3 h c) at 6 h d) at 12 h; (n=3, mean±SD) 
  
 
Fig. 8: Cumulative percentage drug release profiles of LTD prepared floating matrix tablets (F1 to F6); (n=6, mean±SD) 
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Fig. 9: Cumulative percentage drug release profiles of LTD prepared floating matrix tablets (F7 to F12); (n=6, mean±SD) 
 
In vitro dissolution (n=6) 
The prepared LTD floating tablets were exposed to dissolution 
medium (i.e. 0.1N HCl), the medium penetrates the free spaces, 
hydrating the polymer and lipid aid. Finally, it forms a gel-like 
consistency, from which the drug releases slowly for a prolonged 
time [49]. The cumulative percentage of drug releases was 
shown in fig. 8 and fig. 9. The most promising formulation was 
F3 because it cumulative percent of drug release was about 
99.82±0.29 % in 12 h. 
In vivo buoyancy studies (n=3) 
The optimized formulation (F3) was prepared with the same 
compression force as BaSO4. All the physicochemical properties 
were within the pharmacopoeial limits [50]. In vivo, radiographic 
studies were conducted on 3 healthy male human volunteers with a 
glass of water and a standard diet was provided to find out the GRT 
of the tablets. X-ray pictures were taken at different time intervals 
such as 1, 3 and 6 h. 
The X-ray image shows that tablets remain in the stomach for about 6 h 
and which indicate the good floating property (shown in fig. 10). These 
studies revealed that the mean GRT was found to be 6±0.5 h. 
Mechanism of drug release kinetics 
Various models were tested for explaining the kinetics of drug release. 
To analyze the mechanism of the drug release, the dissolution data 
were fitted into zero-order, First order, and Higuchi and Korsmeyer 
Peppas models. In all formulations (F1 to F12), the diffusion exponent 
value was>5. The correlation coefficient (R2) and diffusion exponent 
(n) of release data of all prepared LTD non-effervescent floating 
tablets (i.e. F1 to F12 formulations) were calculated. The optimized 
formulation F3 followed the Peppas model (R2 =0.996) with the non-
Fickian mechanism and it was shown in table 4. 
 
 
Fig. 10: X-ray images of optimized formulation (F3); a) at 30 min; b) at 3 h; c) at 6 h (tablet position was indicated with the circle and 
arrow mark); (n=3, mean±SD) 
 
Table 4: Compilation of the results from all the mathematical models applied to the optimized formulation (F3) 
Formulation code Zero-order First-order Higuchi Hixon crowell Korsmeyer peppas 
R2 R2 n 
*F3 0.978 0.869 0.914 0.862 0.996 0.57 
*Each value represents mean±SD (n=6) 
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CONCLUSION 
The LTD non-effervescent floating tablets were developed by using 
HPMC K15, HPMC K 100 as release retardants and Compritol 888 
ATO, Precirol ATO 5 were used as floating aids. From the above DSC 
and FTIR results, there was no drug and excipient interaction found 
in the formulations. All the formulations showed good 
physicochemical characteristics and F3 formulation was optimized 
based on all parameters. The radio-graphical studies revealed a 
mean GRT of 6±0.5 h. From the above results, it was concluded that 
the formulations retained in the stomach for a longer period and 
extended the drug release. Hence, this dosage form helped to 
improve the absorption of LTD. 
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